



SCIENCE ELEVATED BY INGENUITY

WHERE PASSION MEETS PURPOSE

Corporate Presentation

Nasdaq: PLXP

CONFIDENTIAL

Forward-looking Statements

This presentation includes or incorporates by reference statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements include, but are not limited to information or assumptions about expenses, capital and other expenditures, financing plans, capital structure, cash flow, liquidity, management's plans, goals and objectives for future operations and growth. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases beyond our control and which could cause actual performance or results to differ materially from those expressed in or suggested by forward-looking statements.

Important factors that could cause such differences include, but are not limited to (i) our ability to maintain regulatory approval of VAZALORE 325 mg or VAZALORE 81 mg and obtain regulatory approval for any future product candidates; (ii) the benefits of the use of VAZALORE; (iii) our ability to successfully commercialize our VAZALORE products, or any future product candidates; (iv) the rate and degree of market acceptance of our VAZALORE products or any future product candidates; (v) our ability to successfully build a sales force and commercial infrastructure or collaborate with a firm that has these capabilities; (vi) our ability to compete with companies currently producing NSAIDs and other products; (vii) our reliance on third parties to conduct our clinical studies; (ix) our reliance on third-party contract manufacturers to manufacture and supply our product candidates for us; (xi) our ability to retain and recruit key personnel, including development of a sales and marketing function; and (xii) our ability to obtain and maintain intellectual property protection for our VAZALORE products or any future product candidates.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Confidential

PLx Pharma Management Team



**Natasha
Giordano, RN**
President & CEO



Rita O'Connor, CPA
CFO, Head of
Manufacturing &
Supply Chain



Steven Valentino
Vice President
Trade Sales



Joanne Cotignola
Vice President
Marketing



**Mayme Lou Roettig,
RN, MSN**
Executive Medical
Director



Nicole Godino
National Sales
Director,
Professional



CONFIDENTIAL

OUR MISSION

PLx Pharma is focused on improving the performance of established therapeutic agents with its proprietary PLxGuard™ targeted drug delivery platform

We are driven to transform the standard of care for millions of patients

CONFIDENTIAL

PLx Pharma Investment Highlights

Unique Drug Delivery Platform

PLxGuard for multiple APIs may have the potential to:

- Enhance delivery & extend patent life by optimizing absorption, reducing acute GI injury
- Utilize the often faster and lower cost 505(b)(2) NDA regulatory path

Commercial-Stage Lead Product VAZALORE™

VAZALORE, the first and only FDA-approved liquid-filled aspirin capsule:

- Delivers fast, reliable absorption and platelet inhibition
- Causes fewer gastric erosions/ulcers vs immediate release aspirin as shown in clinical trial*

Large Addressable Market Opportunity

\$10 billion retail market opportunity for VAZALORE:

- Over 40 million patients at risk for vascular disease
- Available in over 30,000 drug, grocery, mass retail and e-commerce sites in U.S.

Financial Position & Key Catalysts

Positioned for growth:


- \$80M in cash, sufficient to support VAZALORE into 2023
- Identify screened compounds where PLxGuard is commercially viable - 2022

Nasdaq: PLXP

CONFIDENTIAL


PLxGuard™ – Innovative Drug Delivery Platform

PLxGuard is intended to reliably release APIs in the duodenum and decrease exposure to the stomach, which is the most susceptible part of the GI tract to NSAID-induced acute gastric injury.




LIMITS DIRECT CONTACT

This complex remains stable in the low pH of the stomach, limiting direct contact of the API with the gastric mucosa.




TARGETED DELIVERY

Once the complex arrives in the duodenum, it dissociates in the higher-pH environment and the API is free to be absorbed.



FAST, PREDICTABLE ABSORPTION

This drug delivery system is intended to predictably release the API in the duodenum to optimize absorption.



REASSEMBLES DURING REFLUX

Even if reflux occurs and the API and lipidic excipients return to the stomach, they reassemble into the complex, limiting direct stomach contact, helping to reduce GI injury.

CONFIDENTIAL

Lead Product Is FDA-approved VAZALORE™



First and only FDA-approved liquid-filled aspirin capsule for over 40 million patients at risk for vascular events with strong patent life

Fast and reliable platelet inhibition addressing the limitations of the current standard of care enteric-coated (EC) aspirin*

Fewer gastric erosions and ulcers than immediate release (IR) aspirin as seen in clinical trials**

Large OTC opportunity with a \$10 billion retail market

World-renowned Scientific Advisory Board chaired by Drs. Deepak Bhatt & Dominick Angiolillo

CONFIDENTIAL

VAZALORE™ Unique Aspirin Delivery System



Bioequivalence to immediate release aspirin with fast, predictable antiplatelet activity




Unique, lipid-based delivery system designed to help **protect the stomach**



Targeted release in the duodenum to optimize absorption

CONFIDENTIAL

VAZALORE™ 325 MG CLINICAL TRIALS



PK/PD Comparison of IR, EC & VAZALORE™¹

Objectives:


- Determine whether formulation dependent bioavailability mediates aspirin non-responsiveness

Methods:

- Randomized, blinded, triple crossover study
40 obese diabetic patients receiving 3 daily doses of:
 - Plain aspirin 325 mg
 - VAZALORE 325 mg
 - EC aspirin 325 mg

Primary Endpoint:

- Time to >99% Thromboxane B₂ (TXB₂) inhibition





VAZALORE achieved 99% TXB₂ inhibition significantly faster than EC aspirin

CONFIDENTIAL

¹ Bhatt DL, et al. Enteric Coating and Aspirin Non-Responsiveness in Patients With Type 2 Diabetes Mellitus. *J Am Coll Cardiol* 2017 Feb; 69(6):603-12

This study design cannot provide data on cardiovascular outcomes

PK/PD Comparison of IR, EC & VAZALORE™¹



CONFIDENTIAL

VAZALORE™ Clinical Summary



**FDA
APPROVED!**

VAZALORE achieved 99% thromboxane B2 inhibition **significantly faster** than enteric coated aspirin*

Absorption with VAZALORE was **5X as high** as enteric coated aspirin*

VAZALORE provided complete antiplatelet effect (99% TXB2) for **almost twice** as many patients as enteric coated aspirin*

VAZALORE caused **fewer erosions and ulcers** than immediate release aspirin**

CONFIDENTIAL

VAZALORE™ Commercial Strategy

Healthcare Professionals (HCPs)

Top Heart/Stroke Hospitals & Affiliated
Clinical Practices





Consumers

#1 influencer is their Cardiologist/HCP
#2 influencer is BRAND familiarity

Retailers

Extensive distribution in over
30,000 retail stores



CONFIDENTIAL

The Opportunity to Improve Aspirin Delivery

NSAIDs are known to cause acute GI injury that often leads to ulceration or perforation of the GI mucosal lining, a factor that limits their use¹

Nearly
25%
of secondary prevention patients with a history of GI issues reported discontinuing aspirin against medical advice because of "stomach issues"²

According to aspirin professional class labeling, enteric coated aspirin products are erratically absorbed from the GI tract³

There hasn't been innovation in the mechanism of aspirin delivery in over 50 years.



CONFIDENTIAL

1. Lichtenberger LM, Barron M, Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. *Drugs Today*. 2009;45(12):877-890.

2. Moberg C, Naesdal J, Svedberg LE, Duchateau D, Harte N. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk. *Patient*. 2011;4(2):103-113.

3. CFR – Code of Federal Regulations Title 21. Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use. Food and Drug Administration; US Dept of Health and Human Services; 2015.

Cornerstone for Healthcare Professional Plan

- **Dedicated cardiovascular care specialist field force**
 - Clinical Cardiologists | Top Heart & Stroke Hospitals
- **World-Class Scientific Advisory Board**
 - Trials | Publications | Education | Influencers
- **Thought leader development**
 - Cardiovascular | Stroke | Peripheral Arterial Disease
- **Medical conferences and education**
 - CME Programming | Scientific Sessions | Expert Panels

**Our Core
Belief:**

**Central to
everything we
do is the
patient!**

CONFIDENTIAL

Scientific Advisory Board



**Deepak L. Bhatt, MD,
MPH, FACC, FAHA,
FSCAI, FESC**



**Dominick J. Angiolillo, MD,
PhD, FACC, FESC, FSCAI**



**P. Gabriel Steg, MD,
FESC, FACC**



**Roxana Mehran, MD,
FACC, FACP, FCCP,
FESC, FAHA, FSCAI**



Byron Cryer, MD



James M. Scheiman, MD




Mark J. Alberts, MD



Jayne Prats, PhD



**Efthymios Deliargyris,
MD, FACC, FESC,
FSCAI**




**Carey Kimmelstiel,
MD, FACC, FACP,
FSCAI**



Todd K. Rosengart, MD

CONFIDENTIAL

Support Pieces Keep VAZALORE™ Top of Mind



325 mg Clinical Data

Professional Labeling

Professional Labeling

Publications

Enteric Coating and Aspirin Nonresponsive Patients With Type 2 Diabetes
Ding L, Shen M, Wu Y, et al. *Journal of Thrombosis and Thrombolysis*. 2019;35(1):124-132.

Clinical Publications and Research
The full clinical story of VAZALORE™ is one of unique and innovative technology. To find links to the peer-reviewed publications, go to VazaloreHCP.com.

Effect of aspirin on platelet function and the pharmacodynamic effects of aspirin
Cohen R, et al. *Journal of Thrombosis and Thrombolysis*. 2019;35(1):124-132.

Availability of aspirin in fasted and fed states of a novel pharmaceutical liquid aspirin capsule formulation
Angulo OJ, et al. *Journal of Thrombosis and Thrombolysis*. 2019;35(1):124-132.

Pharmacokinetic/Pharmacodynamic assessment of a novel pharmaceutical liquid aspirin capsule formulation
Angulo OJ, et al. *Journal of Thrombosis and Thrombolysis*. 2019;35(1):124-132.

Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus
Ding L, et al. *Journal of Thrombosis and Thrombolysis*. 2019;35(1):124-132.

Low-dose aspirin-induced alteration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial
Cohen R, et al. *Journal of Thrombosis and Thrombolysis*. 2019;35(1):124-132.

Impact of dose on platelet inhibition by aspirin in obese patients with type 2 diabetes: a pooled, patient-level analysis of two randomized clinical trials
Angulo OJ, et al. *Journal of Thrombosis and Thrombolysis*. 2019;35(1):124-132.

Abstract presented at: ESCAP, May 19-22, 2019.

Hospital budget impact of switching to an alternative aspirin formulation with improved GI safety for treatment of acute cardiovascular events
Chengappa S, et al. *Value Health*. 2019;22(suppl 1):S103.

Poster presented at: SPCOR, May 19-22, 2019, New Orleans, LA.

Publications



HEART PROTECTION WITH IN MIN

INTRODUCING VAZALORE™—THE FIRST AND ONLY LIQUID-FILLED ASPIRIN CAPSULES™

VAZALORE's unique delivery system is intended to predictably release aspirin in the duodenum and decrease exposure to the stomach, which is the most susceptible part of the GI tract to NSAID-induced acute gastric injury.

No other formulation releases aspirin in this way

Preaspirating the aspirin in VAZALORE to our pharmaceutical liquid presents the aspirin from interacting with similar naturally occurring phospholipids in the stomach lining, helping to prevent acute gastric injury.

VAZALORE

See 325 •

LIMITED DIRECT CONTACT
VAZALORE's capsules release aspirin in the duodenum, away from the stomach lining, helping to prevent acute gastric injury.

TARGETED DELIVERY
Once the capsules reach the duodenum, aspirin is released in the duodenum to prevent acute gastric injury.

FAST PREPARED ABSORPTION
This drug is formulated to be absorbed quickly in the duodenum to prevent acute gastric injury.

REASSURED BY THE SCIENCE
Aspirin is a known gastric irritant. VAZALORE's capsules release aspirin in the duodenum, away from the stomach lining, helping to prevent acute gastric injury.

VAZALORE is available in 81 mg and 325 mg doses

for secondary prevention of vascular events

for secondary prevention of vascular events, acute reduction of fever

Features and Benefits

Samples

CONFIDENTIAL

Conversation Between HCP & Consumer

The VAZALORE consumer:

- Most influenced by **doctor** and **brand familiarity**
- **Concerned** about impact of aspirin on one's stomach
- **Fearful** of having another event

Reaching the consumer:

- **Generate awareness** of VAZALORE as breakthrough delivery designed to help protect the stomach
- **Drive trial**, motivate consumers to **ask doctor** about VAZALORE



CONFIDENTIAL

Consumer Messaging



HEART protection with
your **STOMACH** in mind™

DISCOVER the first and only
liquid-filled **ASPIRIN** capsules™


Consult your healthcare provider before using this product to help prevent another heart attack or clot-related stroke. Use as directed.



HEART
protection
with your
STOMACH
in mind™

- All the benefits of aspirin therapy
- Designed to help protect your stomach

Consult your healthcare provider before using this product to help prevent another heart attack or clot-related stroke. Use as directed.



DISCOVER
the first
and only
liquid-filled
ASPIRIN
capsules™

**ASPIRIN MADE
AMAZING!™**

Consult your healthcare provider before using this product to help prevent another heart attack or clot-related stroke. Use as directed.

CONFIDENTIAL


Content for Digital/E-commerce Efforts



Aspirin can **REDUCE** your **RISK** of another **HEART ATTACK** by **31%**.

VAZALORE™ can help prevent another heart attack.

Consult your healthcare provider before using this product to help prevent another heart attack or clot-related stroke. Use as directed.



Aspirin can help **PREVENT** another clot-related **STROKE** by **22%**.

VAZALORE™ can help prevent another clot-related stroke.

Consult your healthcare provider before using this product to help prevent another heart attack or clot-related stroke. Use as directed.



ACHES and **PAIN** slowing you down?

VAZALORE™ works fast to keep you going.

Consult your healthcare provider before using this product to help prevent another heart attack or clot-related stroke. Use as directed.



81mg
LOW DOSE


FIRST **LIQUID-FILLED** ASPIRIN CAPSULES™
EASY TO SWALLOW

Consult your healthcare provider before using this product to help prevent another heart attack or clot-related stroke. Use as directed.

CONFIDENTIAL

Cornerstone of VAZALORE™ Consumer Plan

National Television



Television plan highlights:

- National plan supports national distribution
- Focus on maximizing reach to build business
- On-air began end of August

“Pinball” creative celebrates VAZALORE innovation

- Metaphor of pinball experience highlights the purposeful delivery of VAZALORE – designed to help protect the stomach, delivering aspirin after it leaves the stomach where it is absorbed to deliver the full benefits of aspirin therapy



CONFIDENTIAL

Where to Buy VAZALORE™



VAZALORE 81 mg 30 ct

Dosage: 81MG | Count: 30 CT

ASPIRIN THERAPY 

Sparta, NJ

Walmart ✓ In Stock **BUY NOW**

CVS pharmacy ✓ In Stock **BUY NOW**

Walgreens ✓ In Stock **BUY NOW**

PriceSpider © PriceSpider 2005-2021 [PriceSpider Terms of Service](#)

Available in over 30,000 retail stores & e-commerce sites in US

Walmart
Save money. Live better.

CVS
pharmacy

Kroger



Walgreens

Albertsons
Companies

amazon

RITE
AID

meijer

Winn✓Dixie.

CONFIDENTIAL

Retail Merchandising & Education Tools

Set the
Shelf



Coming Soon Shelf Placeholders

Shelf Trays

Create In-
Store
Visibility



Displays

HCP
Education
that Drives
Store
Traffic



Retail Pharmacy Education Kits

Doctor Detailing Patient Education Pieces

Ready to
Sell



Open stock units

VAZALORE™ On-Shelf & Displays



CONFIDENTIAL


VAZALORE™ Revenue & Manufacturing



- **Revenue recognized** when the product is received by the retailer
- Reductions to gross revenue include provisions for retailer programs, product returns, prompt pay discounts and coupon redemptions by consumers
- **Extensive distribution in over 30,000 retail stores** across the U.S., many stocking all 3 SKUs as well as displays elsewhere in the store
- Product manufactured by **Thermo Fisher Scientific** in the U.S.

CONFIDENTIAL

VAZALORE Commercial Plan Focused on HCPs, Consumer and Retail



CONFIDENTIAL

VAZALORE™ U.S. Market Opportunity

	Vascular Patients	Diabetic Patients	TOTAL
Target Population ¹ (millions)	27.2	15.6	42.8
Retail Market Size (billions)	\$6.4	\$3.6	\$10.0



VAZALORE™

Market Share	Factory (millions)	Retail (millions)
1%	\$70	\$100
5%	\$350	\$500
10%	\$700	\$1,000

- Vascular Patients: Patients with Atherosclerotic Cardiovascular Disease (ASCVD) defined by having a previous event such as heart attack or stroke or a previous procedure such as cardiac stent, bypass operation, carotid operation or who have imaging evidence of significant vascular disease such as ultrasound, angiogram, etc.
- Diabetic Patients: Patients with diabetes but without evidence of ASCVD who are candidates for aspirin therapy.
- Pricing around \$0.80/day to the patient, around \$25/month.



CONFIDENTIAL

Financial Overview as of 6/30/21

\$80.4 million

Cash & Cash
Equivalents
(Debt free)

\$5.4 million

Operating Cash
Burn
2Q'2021

26.9 million common
shares
(43.3 million fully diluted)

Common Shares
Outstanding

CONFIDENTIAL

PLx Pharma Investment Highlights

Unique Drug Delivery Platform

PLxGuard for multiple APIs may have the potential to:

- Enhance delivery & extend patent life by optimizing absorption, reducing acute GI injury
- Utilize the often faster and lower cost 505(b)(2) NDA regulatory path

Commercial-Stage Lead Product VAZALORE™

VAZALORE, the first and only FDA-approved liquid-filled aspirin capsule:

- Delivers fast, reliable absorption and platelet inhibition
- Causes fewer gastric erosions/ulcers vs immediate release aspirin as shown in clinical trial*

Large Addressable Market Opportunity

\$10 billion retail market opportunity for VAZALORE:

- Over 40 million patients at risk for vascular disease
- Available in over 30,000 drug, grocery, mass retail and e-commerce sites in U.S.

Financial Position & Key Catalysts

Positioned for growth:

- \$80M in cash, sufficient to support VAZALORE into 2023
- Identify screened compounds where PLxGuard is commercially viable - 2022

Nasdaq: PLXP

CONFIDENTIAL

Follow Us

- **PLx Pharma**

- Website: www.plxpharma.com
- Email: info@plxpharma.com
- Phone: 973-409-6541
- LinkedIn: www.linkedin.com/company/plx-pharma-inc-/about

- **Investor Contact**

- Lisa Wilson In-Site Communications, Inc.
lwilson@insitecony.com
212-452-2793

- **VAZALORE™**

- Website www.vazalore.com
- Healthcare professional: www.vazalorehcp.com
- Phone: 1-888-842-3567

- **PLxGuard™ Drug Delivery Platform**

- www.plxpharma.com/our-technology/

CONFIDENTIAL



Thank
you

CONFIDENTIAL